An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)

Cell Death and Disease

Volumn 4, Issue 11, 2013, Pages

  Huang, R Y J ^a,b   Wong, M K ^b   Tan, T Z ^b   Kuay, K T ^b   C Ng, A H ^f   Chung, V Y ^b   Chu, Y S ^f   Matsumura, N ^d   Lai, H C ^e   Lee, Y F ^b   Sim, W J ^f   Chai, C ^b   Pietschmann, E ^a   Mori, S ^b,c   Low, J J H ^a   Choolani, M ^a   Thiery, J P ^b,f,g  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c CANCER INSTITUTE   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^f INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Epithelial mesenchymal transition; Intermediate states; Ovarian cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; NERVE CELL ADHESION MOLECULE; SARACATINIB; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN;

ANOIKIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MESENCHYME; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SPHEROID CELL; SPHEROIDOGENESIS;

ANIMALS; ANOIKIS; ANTINEOPLASTIC AGENTS; BENZODIOXOLES; CADHERINS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; OVARIAN NEOPLASMS; QUINAZOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84889570568     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.442     Document Type: Article

References (61)

1. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454
2. Thiery JP. Metastasis: Alone or together? Curr Biol 2009; 19: R1121-R1123
3. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-142
4. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009; 27: 2059-2068
5. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009; 15: 195-206
6. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715
7. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012; 148: 1015-1028
8. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-981
9. Huang RY, Guilford P, Thiery JP. Early events in cell adhesion and polarity during epithelial-mesenchymal transition. J Cell Sci 2012; 125: 4417-4422
10. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890
11. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6: 813-823
12. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527
13. Tan TZ, Miow QH, Huang RY, Wong MK, Ye J, Lau JA, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med 2013; 5: 983-998
14. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674
15. Moreno-Bueno G, Peinado H, Molina P, Olmeda D, Cubillo E, Santos V, et al. The morphological and molecular features of the epithelial-To-mesenchymal transition. Nat Protoc 2009; 4: 1591-1613
16. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005; 65: 9455-9462
17. Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 2007; 6: 532-541
18. Huang RY, Wang SM, Hsieh CY, Wu JC. Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120-catenin. Int J Cancer 2008; 123: 801-809
19. Meredith JE Jr, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cells 1993; 4: 953-961
20. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-626
21. Guadamillas MC, Cerezo A, del Pozo MA. Overcoming anoikis-pathways to anchorageindependent growth in cancer. J Cell Sci 2011; 124: 3189-3197
22. Onder TT, G PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cahderin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008; 68: 3645-3654
23. Gauger KJ, H JM, T MA, Schneider SS. Down-regulation of sfrp1 in a mammary epithelial cell line promotes the development of a cd44high/cd24low population which is invasive and resistant to anoikis. Cancer Cell Ints 2009; 9: 11
24. Frisch SM, Cieply B. Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci 2013; 126: 21-29
25. Chua KN, Poon KL, Lim J, Sim WJ, Huang RY, Thiery JP. Target cell movement in tumor and cardiovascular diseases based on the epithelial- mesenchymal transition concept. Adv Drug Deliv Rev 2011; 63: 558-567
26. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010; 10: 268-278
27. Davidson B, Trope CG, Reich R. Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol 2012; 2: 33
28. Matsumura N, Huang Z, Mori S, Baba T, Fujii S, Konishi I, et al. Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res 2011; 21: 74-82
29. Ahmed N, Thompson EW, Quinn MA. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: An exception to the norm. J Cell Physiol 2007; 213: 581-588
30. Chua KN, Sim WJ, Racine V, Lee SY, Goh BC, Thiery JP. A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. PLoS One 2012; 7: E33183
31. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208
32. Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med 2011; 30: 2409-2421
33. Leroy P, Mostov KE. Slug is required for cell survival during partial epithelial-mesenchymal transition of HGF-induced tubulogenesis. Mol Biol Cell 2007; 18: 1943-1952
34. Peinado H, Olmeda D, Cano A. Snail Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-428
35. Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TR Jr., Ruff LE, et al. Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol 2001; 159: 2071-2080
36. Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010; 17: 298-310
37. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009; 28: 151-166
38. Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A, et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatinremodeling protein BRG1. Oncogene 2010; 29: 3490-3500
39. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601
40. Mihira H, Suzuki HI, Akatsu Y, Yoshimatsu Y, Igarashi T, Miyazono K, et al. TGF-beta-induced mesenchymal transition of MS-1 endothelial cells requires Smad-dependent cooperative activation of Rho signals and MRTF-A. J Biochem 2012; 151: 145-156
41. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011; 30: 1436-1448
42. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-Type-specific regulators of FGFR2 splicing. Mol Cell 2009; 33: 591-601
43. Cieply B, Riley P, Pifer PM, Widmeyer J, Addison JB, Ivanov AV, et al. Suppression of the epithelial-mesenchymal transition by Grainyhead-like-2. Cancer Res 2012; 72: 2440-2453
44. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-5828
45. Chen LM, Verity NJ, Chai KX. Loss of prostasin (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT). BMC Cancer 2009; 9: 377
46. Cheng H, Fukushima T, Takahashi N, Tanaka H, Kataoka H. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membranebound serine proteinases. Cancer Res 2009; 69: 1828-1835
47. Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, et al. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One 2011; 6: E21650
48. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett 2011; 300: 66-78
49. Maeyama M, Koga H, Selvendiran K, Yanagimoto C, Hanada S, Taniguchi E, et al. Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition. Cancer 2008; 113: 2823-2831
50. White LR, Blanchette JB, Ren L, Awn A, Trpkov K, Muruve DA. The characterization of alpha5-integrin expression on tubular epithelium during renal injury. Am J Physiol Renal Physiol 2007; 292: F567-F576
51. Maschler S, Wirl G, Spring H, Bredow DV, Sordat I, Beug H, et al. Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene 2005; 24: 2032-2041
52. Nam EH, Lee Y, Park YK, Lee JW, Kim S. ZEB2 upregulates integrin alpha5 expression through cooperation with Sp1 to induce invasion during epithelial-mesenchymal transition of human cancer cells. Carcinogenesis 2012; 33: 563-571
53. Boyer B, Tucker GC, Valles AM, Gavrilovic J, Thiery JP. Reversible transition towards a fibroblastic phenotype in a rat carcinoma cell line. Int J Cancer Suppl 1989; 4: 69-75
54. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop-A motor of cellular plasticity in development and cancer? EMBO Rep 2010; 11: 670-677
55. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 2007; 185: 191-203
56. Evseenko D, Zhu Y, Schenke-Layland K, Kuo J, Latour B, Ge S, et al. Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells. Proc Natl Acad Sci USA 2010; 107: 13742-13747
57. Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S, et al. An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. Embo J 2010; 29: 3286-3300
58. Warzecha CC, Carstens RP. Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-To-mesenchymal transition (EMT). Semin Cancer Biol 2012; 22: 417-427
59. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome 2008; 14: 5198-5208
60. Network TCGAR. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615
61. Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 2011; 6: E16186